Skip to main content
Premium Trial:

Request an Annual Quote

DiagnoCure Retains JMP to Help with Lab Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure this week said that it has retained the financial services firm JMP Securities to help it increase business for its DiagnoCure Oncology Laboratories.

In a statement, Yves Fradet, president and chief medical officer of DiagnoCure, added that JMP will help the company "determine the most effective method to roll out our colorectal cancer disease management program."

Based in West Chester, Penn., the oncology lab is a subsidiary of DiagnoCure and launched its Previstage GCC Colorectal Cancer Staging Test in 2008. The test is currently undergoing additional testing for confirmation of its clinical utility, DiagnoCure said.

The laboratory recently received approval from New York state to use the Previstage test on commercial samples originating in New York, opening up a significant market for the firm, it said at the time.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.